Anticoagulant therapy being the most conventional form of therapeutic intervention is the
cornerstone for the treatment and prevention of various ailments including Atrial Fibrillation (AF),
Acute Coronary Syndrome (ACS), Venous Thromboembolism (VTE) and patients undertaking
cardiac procedures1. Bleeding is the principal complication of anticoagulants even though used
within its therapeutic limit. An innovative tool HAS-BLED score come up with the assessment of
bleeding risk among patients under anticoagulant therapy supporting the physicians in a better
clinical decision making2,3. The objective is to evaluate drug use and bleeding risk of anticoagulant
drugs using HAS-BLED Score among geriatric patients. A prospective observational study was
conducted in a tertiary care hospital among hundred patients for a period of six months. It was
found that 61% were males and 49% were females. Most of the patients were from the age group
of 65-70 (53%), 71-75 (31%) and least less than 75 (16%). The most commonly prescribed dosage
form was parenteral (79%) and drug was heparin (52%). The bleeding risk of twenty patients
taking warfarin was assessed using HAS- BLED Score, the risk categories shows greater than or
equal to 3 (60%) high risk and score between 1-2 (40%) moderate risk. Drug use pattern of
anticoagulants needs uninterrupted and repeated surveillance not only to discern therapeutic
efficacy but also to scrutinize potential adverse drug reaction. From the HAS-BLED score
distribution of patients taking warfarin conveys the need to monitor the parameters especially INR
before and after initiation of anticoagulant therapy.
Keywords: Drug Use Evaluation, Anticoagulant Therapy, HAS-BLED Score, Atrial Fibrillation,
Bleeding Risk, Warfarin